Benzinga | May 4, 2021 05:30PM EDT

Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress

Veracyte, Inc. (NASDAQ:VCYT) announced today that new data relating to the Prosigna(r) Breast Cancer Gene Signature Assay will be presented at the European Society of Medical Oncology (ESMO) Breast Cancer Virtual Congress 2021 taking place May 5-8.

"New data accepted for presentation at this year's ESMO Breast Cancer Congress provide further evidence for the importance of genomic testing in breast cancer, particularly to help physicians and patients make better informed treatment decisions based on the unique biology of individual patients' tumors," said Bonnie Anderson, Veracyte's chairman and chief executive officer. "We believe such data strengthen the backdrop for our Prosigna Breast Cancer Gene Signature Assay, and greatly appreciate the breast cancer experts who led and participated in these studies."